135598-68-4

Basic information

• Product Name: CNDAC
• Synonyms: 4-Amino-1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone
• CAS NO: 135598-68-4
• Molecular Formula: C₁₀H₁₂N₄O₄
• Molecular Weight: 252.22668
• EINECS: -0
• Mol File: 135598-68-4.mol

Chemical Properties

• Boiling Point: 596.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.75±0.1 g/cm3(Predicted)
• PKA: 12.78±0.70(Predicted)
• CAS DataBase Reference: CNDAC(CAS DataBase Reference)
• NIST Chemistry Reference: CNDAC(135598-68-4)
• EPA Substance Registry System: CNDAC(135598-68-4)

Safety Data

• Hazardous Substances Data: 135598-68-4(Hazardous Substances Data)

Usage

Uses

Used in Cancer Treatment:
CNDAC is used as an anti-cancer agent for its ability to inhibit DNA synthesis, making it a potential candidate for the treatment of various types of cancer.
Used in Combination Therapy:
CNDAC is used in combination therapy with other anti-cancer agents to enhance the overall effectiveness of cancer treatment. Research has shown encouraging results for its potential in combination therapy, and further studies are being conducted to explore its full potential in this area.

Upstream product

• 135598-72-0 N⁴-acetyl-1-(2-C-cyano-2-deoxy-β-D-arabinofuranosyl)cytosine 
• 134665-72-8 2'-C-cyano-2'-deoxy-1-β-D-arabinofuranosylcytosine hydrochloride 
• 140859-16-1 N⁴-acetyl-1-<3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-erythro-pentofuran-2-ulosyl>cytosine 
• 135598-71-9 N⁴-acetyl-1-<2-C-cyano-2-deoxy-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl>cytosine 

Downstream Products

• 71-30-7 Cytosine 
• 151823-14-2 sapacitabine 

Relevant articles and documents

PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHEIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE

The present invention relates to a process for preparing a compound of formula 682-4, said process comprising the steps of: (i) converting a compound of formula 682-1 into a compound of formula 682-2'; (ii) converting said compound of formula 682-2' into a compound of formula 682-3; and (iii) converting said compound of formula 682-3 into a compound of formula 682-4. Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4 -palmitoyl-1-β-D-arabmofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.

INTERMEDIATE AND PROCESSES INVOLVED IN THE PREPARATION OF 2 ' -CYANO-2 ' -DE0XY-N4-PALMIT0YL-1-BETA-ARABIN0FURAN0SYLCYTOSINE

The present invention relates to a process for preparing a compound of formula (682-6'), said process comprising the steps of: formula (682-4), (682-5), (682-6'): (i) converting a compound of formula (682-4) into a compound of formula (682-5); and (ii) converting said compound of formula (682-5) into a compound of formula (682- 6'). Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4-palmitoyl-l-β-D-arabinofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.

CRYSTALLINE PYRIMIDINE NUCLEOSIDE DERIVATIVE SUSPENSIONS IN CAPSULES

The present invention relates to a pharmaceutical formulation which comprises (i) a capsule, and (ii) a core comprising crystalline 2′-cyano-2′-deoxy-N4-palmitoyl-1-β-D-arabinofuranosylcytosine and a liquid carrier.

Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-β-D- arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum

Design, synthesis, and tumor cell growth inhibitory effects of 2'-C- cyano-2'-deoxy-1-β-D-arabinofuranosyl derivatives of cytosine (1i, CNDAC), thymine (6a), uracil (6c), and adenine (6d) have been described. The synthesis of the target compounds was achi